DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Phase 1

Completed

Conditions: Mantle Cell Lymphoma
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions: Drug: TGR-1202
Drug: Ibrutinib

First Posted Date: 2014-10-20

Last Posted Date: 2024-11-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT02268851

Locations: 🇺🇸
Pacific Cancer Care, Monterey, California, United States
🇺🇸
St. Francis Hospital and Cancer Center, Hartford, Connecticut, United States
🇺🇸
Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States

and more 2 locations

Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate

Phase 2

Completed

Conditions: Prostate Adenocarcinoma
Prostate Cancer
High Risk Prostate Cancer

Interventions: Drug: Enzalutamide
Drug: Abiraterone Acetate
Drug: Prednisone
Drug: Leuprolide Acetate

First Posted Date: 2014-10-20

Last Posted Date: 2022-04-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 75

Registration Number: NCT02268175

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Impact of Cerebellar Mass Resection on Pain Processing

Completed

Conditions: Cerebellar Neoplasm

Interventions: Device: Medoc Advanced Medical Systems PATHWAY Model ATS
Procedure: Cold water bath
Device: MRI scanner
Other: Questionnaires

First Posted Date: 2014-10-10

Last Posted Date: 2018-02-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 24

Registration Number: NCT02261649

Locations: 🇺🇸
Boston Children's Hospital, Waltham, Massachusetts, United States

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

Phase 2

Completed

Conditions: Breast Cancer
Brain Tumor - Metastatic

Interventions: Drug: Cabozantinib
Drug: Trastuzumab

First Posted Date: 2014-10-09

Last Posted Date: 2021-05-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 36

Registration Number: NCT02260531

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia

Phase 2

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Leukemia

Interventions: Drug: Ibrutinib
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2014-09-29

Last Posted Date: 2025-02-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 85

Registration Number: NCT02251548

Locations: 🇺🇸
West Michigan Cancer Center, Kalamazoo, Michigan, United States
🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 5 locations

Impact of Radiation Therapy on Breast Conservation in DCIS

Completed

Conditions: DCIS

First Posted Date: 2014-09-25

Last Posted Date: 2019-09-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 3436

Registration Number: NCT02248662

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Harvard Pilgrim Health Care Institute, Boston, Massachusetts, United States
🇺🇸
Dartmouth College, Hanover, New Hampshire, United States

and more 1 locations

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Phase 1

Completed

Conditions: Anaplastic Thyroid Cancer
Thyroid Cancer
Differentiated Thyroid Cancer

Interventions: Drug: MLN0128

First Posted Date: 2014-09-19

Last Posted Date: 2024-01-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 46

Registration Number: NCT02244463

Locations: 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Michigan Medical School, Ann Arbor, Michigan, United States

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Phase 1

Completed

Conditions: Castration-resistant Prostate Cancer

Interventions: Drug: Crizotinib
Drug: Enzalutamide

First Posted Date: 2014-08-04

Last Posted Date: 2022-01-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 24

Registration Number: NCT02207504

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Everolimus for Cancer With TSC1 or TSC2 Mutation

Phase 2

Completed

Conditions: TSC1
Tuberous Sclerosis Complex
MTOR
TSC2

Interventions: Drug: Everolimus

First Posted Date: 2014-07-28

Last Posted Date: 2020-09-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT02201212

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD

Phase 2

Completed

Conditions: Graft Versus Host Disease

Interventions: Drug: Natalizumab
Drug: Methylprednisolone

First Posted Date: 2014-06-26

Last Posted Date: 2020-04-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT02176031

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy